Antiviral research最新文献

ISAR opinion: Product development partnerships to fund pandemic antiviral research 专家组意见：资助大流行性抗病毒研究的产品开发伙伴关系

IF 4.5 2区医学

Antiviral research Pub Date : 2025-04-22 DOI: 10.1016/j.antiviral.2025.106166

Luis M. Schang, the International Society for Antiviral Research (ISAR)

引用次数: 0

Meeting report: Seventh summer school on innovative approaches for identification of antiviral agents (IAAASS) 会议报告：第七届抗病毒药物鉴定创新方法暑期学校（IAAASS）

IF 4.5 2区医学

Antiviral research Pub Date : 2025-04-18 DOI: 10.1016/j.antiviral.2025.106170

Angela Corona , Valeria Cagno , Nicole Grandi , Elisa Fanunza , Francesca Esposito , Kathie L. Seley-Radtke , Enzo Tramontano

{"title":"Meeting report: Seventh summer school on innovative approaches for identification of antiviral agents (IAAASS)","authors":"Angela Corona , Valeria Cagno , Nicole Grandi , Elisa Fanunza , Francesca Esposito , Kathie L. Seley-Radtke , Enzo Tramontano","doi":"10.1016/j.antiviral.2025.106170","DOIUrl":"10.1016/j.antiviral.2025.106170","url":null,"abstract":"<div><div>The 7th Summer School on Innovative Approaches for the Identification of Antiviral Agents (IAAASS) was held at the Sardegna Ricerche Research Park in Santa Margherita di Pula, Sardinia, Italy from September 23–27, 2024, organized by the Co.S.Me.Se, the Department of Life and Environmental Sciences of the University of Cagliari and Sardegna Ricerche in the frame of Next Generation Virology initiative and the Antiviral DiscoVery Initiatives: Educating Next-Gen Scientists (ADVISE Project) 2024. The Summer School is proposed as an informal high-level event comprehensive of the different scientific souls involved in the design and development of new antiviral drug-candidates and their validation and progression up-to the clinic, and it offers, to a limited number of early career scientists, high-level lectures, networking and mentoring opportunities by internationally recognized scientists in a highly interactive environment.</div><div>The meeting was a very successful event that convened 21 senior speakers with internationally recognized experience in the field of antiviral research and 60 Early Career Scientists (graduated master students, PhD students and early post doctoral researchers) from 13 different countries (Belarus, Belgium, Brazil, Bulgaria, Chile, Denmark, Germany, Italy, Russian Federation, Spain, Switzerland, The Netherlands, and the USA).</div></div>","PeriodicalId":8259,"journal":{"name":"Antiviral research","volume":"238 ","pages":"Article 106170"},"PeriodicalIF":4.5,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143864473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lysergol exerts potent antiviral activity against the emerging Oropouche virus in vitro 麦芽糖醇在体外对新出现的Oropouche病毒具有有效的抗病毒活性

IF 4.5 2区医学

Antiviral research Pub Date : 2025-04-18 DOI: 10.1016/j.antiviral.2025.106171

Lais D. Coimbra , Jacqueline F. Shimizu , Alice Nagai , Alexandre Borin , Marina A. Fontoura , Juan O. Concha , Luiza Leme , Ketleen Lucas do Carmo , Leonardo C. de Oliveira , Adriana S. Soprano , Jaqueline S. Felipe , Amanda B. Silva , Julia Forato , Gabriel C. Scachetti , Colin M. Crump , Lívia Sacchetto , Maurício L. Nogueira , Eduardo H.S. Bezerra , Samuel L. Guimarães , Artur T. Cordeiro , Rafael Elias Marques

{"title":"Lysergol exerts potent antiviral activity against the emerging Oropouche virus in vitro","authors":"Lais D. Coimbra , Jacqueline F. Shimizu , Alice Nagai , Alexandre Borin , Marina A. Fontoura , Juan O. Concha , Luiza Leme , Ketleen Lucas do Carmo , Leonardo C. de Oliveira , Adriana S. Soprano , Jaqueline S. Felipe , Amanda B. Silva , Julia Forato , Gabriel C. Scachetti , Colin M. Crump , Lívia Sacchetto , Maurício L. Nogueira , Eduardo H.S. Bezerra , Samuel L. Guimarães , Artur T. Cordeiro , Rafael Elias Marques","doi":"10.1016/j.antiviral.2025.106171","DOIUrl":"10.1016/j.antiviral.2025.106171","url":null,"abstract":"<div><div>Oropouche virus (OROV) has caused a new outbreak, with thousands of cases of febrile disease in South and Central America, including regions where the virus was not detected before. Oropouche fever is a neglected mosquito-borne disease that still lacks options for antiviral treatment. We developed a high-throughput screening phenotypic assay using human hepatocyte-derived HuH-7.0 cells to screen over 7700 compounds against OROV infection. We identified 13 hit compounds that were protective against OROV-induced cytopathic effect in cell culture, of which 3 were confirmed: lysergol, amiloride hydrochloride, and pyridostatin TFA, with EC50 values below 2 μM. Orthogonal assays indicate that both lysergol and pyridostatin present antiviral activity against OROV in HuH-7.0 and T24 cell lines, but lysergol is far more potent, causing up to a 100,000-fold reduction in viral load in the low micromolar range. Mechanistic studies indicate that the antiviral effect of lysergol affects early stages of viral replication, and that lysergol is also active against a recently isolated OROV strain. In conclusion, our phenotypical screening campaign led to the identification of a first-in-class compound with potent antiviral activity against the emerging OROV in cell culture. We conclude that high-throughput screening assays can be implemented in response to the emergence of arboviruses and accelerate the discovery of candidate treatments.</div></div>","PeriodicalId":8259,"journal":{"name":"Antiviral research","volume":"238 ","pages":"Article 106171"},"PeriodicalIF":4.5,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143869535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inhibition of MAPK signaling suppresses cytomegalovirus reactivation in CD34+ Kasumi-3 cells 抑制MAPK信号可抑制CD34+ Kasumi-3细胞中巨细胞病毒的再激活

IF 4.5 2区医学

Antiviral research Pub Date : 2025-04-16 DOI: 10.1016/j.antiviral.2025.106169

Vargab Baruah , Benjamin A. Krishna , Michael C. Kelly , Xu Qi , Christine M. O'Connor

引用次数: 0

Mechanisms of action of repurposed Ebola virus antivirals – the roles of phospholipidosis and cholesterol homeostasis 重组埃博拉病毒抗病毒药物的作用机制——磷脂病和胆固醇稳态的作用

IF 4.5 2区医学

Antiviral research Pub Date : 2025-04-15 DOI: 10.1016/j.antiviral.2025.106167

Jamie A. Kelly , Virginia Aida-Ficken , Laura K. McMullan , Payel Chatterjee , Punya Shrivastava-Ranjan , Stéphane Marot , M. Harley Jenks , Michael K. Lo , Joel M. Montgomery , Christina F. Spiropoulou , Mike Flint

{"title":"Mechanisms of action of repurposed Ebola virus antivirals – the roles of phospholipidosis and cholesterol homeostasis","authors":"Jamie A. Kelly , Virginia Aida-Ficken , Laura K. McMullan , Payel Chatterjee , Punya Shrivastava-Ranjan , Stéphane Marot , M. Harley Jenks , Michael K. Lo , Joel M. Montgomery , Christina F. Spiropoulou , Mike Flint","doi":"10.1016/j.antiviral.2025.106167","DOIUrl":"10.1016/j.antiviral.2025.106167","url":null,"abstract":"<div><div>Cell-based drug repurposing screens have been a common approach to identifying compounds with antiviral properties. For Ebola virus (EBOV), such screens yield unexpectedly high hit rates. We investigated two mechanisms underlying the anti-EBOV activities of repurposed compounds. Phospholipidosis (PLD) is excessive accumulation of cellular lipids that confounds screens for SARS-CoV-2. We performed a meta-analysis of published screens and supplemented these with our own using infectious EBOV at biosafety level-4. A list of nearly 400 hit compounds from seven anti-EBOV screens was compiled. Most (63 %) of these hits were predicted to induce PLD, and their anti-EBOV activities broadly correlated with PLD induction. PLD-inducing compounds did not inhibit infection by several other highly pathogenic viruses, suggesting that PLD was not a confounding factor for screens against Lassa, Crimean-Congo hemorrhagic fever, and Rift Valley fever viruses. Of four cells lines tested, HeLa cells were the least susceptible to PLD induction. In addition to PLD, many of the hit compounds identified disrupt cholesterol homeostasis. Previous research found inhibition of cholesterol synthesis by statins blocked EBOV infection. To understand if compounds inhibiting this mechanism could contribute to high hit rates, we further examined this pathway. We identified multiple additional inhibitors of cholesterol biosynthesis, that also blocked EBOV infection, albeit with varying potency and cytotoxicity across cell lines. EBOV inhibitors that acted through this mechanism were suppressed by the addition of exogenous cholesterol. Our findings help define the effects that contribute to anti-EBOV activities and hence facilitate the selection of lead molecules suitable for subsequent development.</div></div>","PeriodicalId":8259,"journal":{"name":"Antiviral research","volume":"238 ","pages":"Article 106167"},"PeriodicalIF":4.5,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143848676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anti-HCV antibodies: A battle for breadth and potency 抗hcv抗体：一场广度和效力之战

IF 4.5 2区医学

Antiviral research Pub Date : 2025-04-15 DOI: 10.1016/j.antiviral.2025.106165

Elham Jamali , Ahmed Abdul Quadeer , Nicodemus Tedla , Matthew R. McKay , Andrew Lloyd , Melanie R. Walker , Rowena A. Bull

引用次数: 0

Truncated rotavirus VP4 proteins induce stronger protective immunity compared to P2 - VP8 in animal models 在动物模型中，截断的轮状病毒VP4蛋白比P2 - VP8蛋白诱导更强的保护性免疫。

IF 4.5 2区医学

Antiviral research Pub Date : 2025-04-05 DOI: 10.1016/j.antiviral.2025.106156

Yaling Chen , Guoxing Luo , Feibo Song , Xuechun Wang , Shiyin Zhang , Shengxiang Ge , Tingdong Li , Jun Zhang , Ningshao Xia

{"title":"Truncated rotavirus VP4 proteins induce stronger protective immunity compared to P2 - VP8 in animal models","authors":"Yaling Chen , Guoxing Luo , Feibo Song , Xuechun Wang , Shiyin Zhang , Shengxiang Ge , Tingdong Li , Jun Zhang , Ningshao Xia","doi":"10.1016/j.antiviral.2025.106156","DOIUrl":"10.1016/j.antiviral.2025.106156","url":null,"abstract":"<div><div>Group A rotavirus (RVA) is the primary causative agent of acute gastroenteritis (AGE) in children under five years of age, resulting in over 120,000 deaths annually. In previous studies, we identified truncated VP4∗ as a potentially more promising vaccine candidate compared to VP8∗ and VP5∗. This study aimed to compare the immunogenicity and protective efficacy of VP4∗ and P2-VP8, the most advanced recombinant rotavirus vaccine undergoing phase 3 clinical trial in various animal models, including mice, guinea pigs, rabbits, and piglets. The results indicated that the binding antibodies and neutralizing antibodies induced by VP4∗ were significantly higher levels compared to P2-VP8. Immunization with VP4∗ provided 100 % protection for mice against challenges with EDIM and LLR strains. Additionally, we were intrigued to discover that the VP4∗ antibody not only inhibited virus adsorption but also prevented the virus from entering cells following pre-adsorption. In summary, VP4∗ demonstrates greater immunogenicity and protective efficacy compared to P2-VP8, making it a more promising candidate antigen for recombinant rotavirus vaccines.</div></div>","PeriodicalId":8259,"journal":{"name":"Antiviral research","volume":"238 ","pages":"Article 106156"},"PeriodicalIF":4.5,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Salicylamide derivative JMX0312 protects immunosuppressed Syrian hamsters against adenovirus lethal challenge 水杨胺衍生物JMX0312保护免疫抑制的叙利亚仓鼠免受腺病毒致命攻击

IF 4.5 2区医学

Antiviral research Pub Date : 2025-04-02 DOI: 10.1016/j.antiviral.2025.106155

Marta Carretero-Ledesma , Jun Li , Javier Martín-Escolano , Soraya Herrera-Espejo , Jimin Xu , Haiying Chen , Caridad Díaz-Navarro , Jerónimo Pachón , Javier Sánchez-Céspedes , Jia Zhou , María Eugenia Pachón-Ibáñez

{"title":"Salicylamide derivative JMX0312 protects immunosuppressed Syrian hamsters against adenovirus lethal challenge","authors":"Marta Carretero-Ledesma , Jun Li , Javier Martín-Escolano , Soraya Herrera-Espejo , Jimin Xu , Haiying Chen , Caridad Díaz-Navarro , Jerónimo Pachón , Javier Sánchez-Céspedes , Jia Zhou , María Eugenia Pachón-Ibáñez","doi":"10.1016/j.antiviral.2025.106155","DOIUrl":"10.1016/j.antiviral.2025.106155","url":null,"abstract":"<div><div>Despite the fact that human adenovirus (HAdV) causes severe infections in immunosuppressed and immunocompetent individuals, especially in children, there is currently no specific treatment for these infections. Previously we reported a new salicylamide analogue, JMX0312, as a potent inhibitor of HAdV infection with low cytotoxicity <em>in vitro</em>. Here we evaluate the <em>in vivo</em> efficacy and safety of this molecule in the immunosuppressed Syrian hamster model of HAdV infection. JMX0312 administration at a dose of 6.25 mg/kg did not affect the body weight of the animals, and reduced the viral load in liver and blood in a similar way than cidofovir. Also, JMX0312 reduced the mortality of the animals, although in a lesser extent than cidofovir, a drug used to treat these infections that must be subject to rigorous monitoring due to its high toxicity and whose used is not approved in children. Our findings highlight the potential of this new antiviral agent for the treatment of HAdV infections, paving the way for future pre-clinical and clinical trial development towards a safer and more effective treatment against HAdV-associated infections.</div></div>","PeriodicalId":8259,"journal":{"name":"Antiviral research","volume":"238 ","pages":"Article 106155"},"PeriodicalIF":4.5,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143786189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comprehensive preclinical characterization of IPB29, a pan-coronavirus fusion inhibitor under clinical trials 临床试验中泛冠状病毒融合抑制剂IPB29的临床前综合表征

IF 4.5 2区医学

Antiviral research Pub Date : 2025-03-28 DOI: 10.1016/j.antiviral.2025.106154

Yuanmei Zhu , Zhongcai Gao , Xiaoli Feng , Yue Hu , Nian Liu , Chao Liu , Qiaojiang Yang , Qingcui Zou , Minghua Li , Gengshen Song , Yuxian He

{"title":"Comprehensive preclinical characterization of IPB29, a pan-coronavirus fusion inhibitor under clinical trials","authors":"Yuanmei Zhu , Zhongcai Gao , Xiaoli Feng , Yue Hu , Nian Liu , Chao Liu , Qiaojiang Yang , Qingcui Zou , Minghua Li , Gengshen Song , Yuxian He","doi":"10.1016/j.antiviral.2025.106154","DOIUrl":"10.1016/j.antiviral.2025.106154","url":null,"abstract":"<div><div>IPB29 is a lipopeptide-based coronavirus fusion inhibitor with the potent, broad-spectrum antiviral activity, and it has already been advanced to phase III clinical trials for the treatment of SARS-CoV-2 infection. We recently reported its design strategy and initial preclinical characterization; herein, we focused on characterizing its efficacies against newly-emerged Omicron variants, as well as its chronic general toxicity, toxicokinetics, immunogenicity, and reproductive toxicity in animal models. As anticipated, IPB29 demonstrated improved activity in inhibiting JN.1 and KP.2 variants, effectively blocking cell fusion and pseudovirus infections. Nebulized inhalation of IPB29 exhibited high therapeutic efficacy against live BA.5 and EG.5.1 infections in Syrian hamsters. The 26-week toxicity studies revealed that nebulized IPB29 has a favorable safety profile, with well-characterized toxicokinetics in SD rats and Beagle dogs. Notably, short-term nebulization of IPB29 did not elicit anti-drug antibody (ADA) responses in either species. However, IPB29-specific antibodies were detected after long-term administration. Finally, a three-stage reproductive toxicity study in SD rats indicated that IPB29 had no significant toxic effects on fertility, embryo-fetal development, or the development of offspring. In summary, our findings demonstrate that IPB29 is a safe and effective SARS-CoV-2 inhibitor with promising potential for clinical applications.</div></div>","PeriodicalId":8259,"journal":{"name":"Antiviral research","volume":"237 ","pages":"Article 106154"},"PeriodicalIF":4.5,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143738498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hijacking JAKis: JAK inhibitors as potential antiviral molecules, a mini review 劫持JAKis：作为潜在抗病毒分子的JAK抑制剂，综述。

IF 4.5 2区医学

Antiviral research Pub Date : 2025-03-27 DOI: 10.1016/j.antiviral.2025.106153

Claudie Eber, Eloi R. Verrier

引用次数: 0